about
Nonlinear partial differential equations and applications: The mechanism of topoisomerase I poisoning by a camptothecin analogTherapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenograftsEffective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administrationThe bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitorA phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sitesComparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer.SCT1 mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I.Canine spontaneous glioma: a translational model system for convection-enhanced deliveryMedicinal plants and cancer chemoprevention.Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells.In-vitro Cellular Uptake and Transport Study of 9-Nitrocamptothecin PLGA Nanoparticles Across Caco-2 Cell Monolayer ModelInhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles.Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group studyEvaluation of self-assembled HCPT-loaded PEG-b-PLA nanoparticles by comparing with HCPT-loaded PLA nanoparticlesDual Inhibitors Against Topoisomerases and Histone DeacetylasesInduction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitorsVariation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.Determinants of CPT-11 and SN-38 activities in human lung cancer cellsMultiple event activation of a generic prodrug trigger by antibody catalysis.Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan.Camptothecin nanocolloids based on N,N,N-trimethyl chitosan: efficient suppression of growth of multiple myeloma in a murine model.Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy.Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells.CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.Tumor regression achieved by encapsulating a moderately soluble drug into a polymeric thermogelProduction of camptothecin in cultures of Chonemorpha grandiflora.Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.Extreme Activity of Drug Nanocrystals Coated with A Layer of Non-Covalent Polymers from Self-Assembled Boric Acid.Current perspectives on camptothecins in cancer treatmentCamptothecin-based nanodrug delivery systems.iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery.Effect of CPT-11 on lipid peroxide level in mouse tissues.No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer.Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts.Abundance of Cytochromes in Hepatic Extracellular Vesicles Is Altered by Drugs Related With Drug-Induced Liver Injury
P2860
Q27639935-F8872159-AEAE-4769-AF1A-372CB32652DDQ28379054-32EF65C6-1AF2-40D3-BE89-CF83594EED07Q30667530-6B8225C1-8EC8-4F8D-B684-C614484C3469Q33495553-0EF1DA53-EB41-4723-AE5F-B85C8EDFB852Q33500497-58B3E264-2DE7-460E-A885-38A3C8E802E2Q33504409-BA9B4805-B43B-4A34-9DCA-C4218DDC8ABBQ33932878-89C87178-E16A-4A0D-B68B-09705EEB2BDDQ34110928-30AF9964-46D5-4CE6-8015-AD8563868143Q34114381-A4191BE6-E0C0-48D6-9FCF-D53B35167C08Q34133134-D1B4B107-BDE2-4B0E-AAA1-D75424390447Q34162937-44C2F2F5-F504-4905-9B52-7F3F29585384Q34616111-2B92C881-7115-430F-8EDA-7BE0AEA201D2Q35046472-B1A07932-D17E-4C34-BF73-18C0D7AD826FQ35119565-DBE5C1E2-880F-43EF-996B-0D8005B2E432Q35565630-10246310-E698-4163-9BEC-352829C98A14Q35668046-5256954E-DFCD-4E4C-8022-BCE4CEABD2EAQ35821010-B423BFE3-028E-4A06-974A-A45DEFD52862Q36114881-9D674D1B-DF3A-4C86-A46B-BF9335BDD73EQ36135838-CE692538-43D7-49ED-B440-F8C4741AF73CQ36292082-76CEAA1F-C8EA-4624-B1D4-4F77DAF8EDB6Q36292935-D47AA795-BEBC-474C-9A7A-206911AD0989Q36385720-83753145-5E6B-47AF-8109-B6BA247D992EQ36420152-A26E50FE-25CB-4F51-9F29-332EF9B73713Q36642304-A6891A30-D584-4229-9363-D95B077DB692Q37141536-E2BFE36B-9EE9-4747-B95E-5EFD1F409CA6Q37388109-2756E4CF-3142-44C2-8EB3-B188FEFB6157Q37402888-15891930-E5BE-44E8-82C6-D2E4B0A4DA07Q38979496-32E3C78A-86DC-4D40-A806-A7CB52C8EF48Q40324636-359B7ECC-2CFA-4D61-AF4B-752A27ED8D6EQ40978962-7ED6489B-4D2F-40BD-B772-C55B3A7057FBQ41946092-8DCDB08B-CA2C-485E-B1F5-F5D82C6E2547Q42715927-F75EABA7-C8EB-423B-BF53-4C839DCE1E87Q47700115-B0763ED4-1C35-4608-863B-A7FC961EFA79Q47815925-9A38BF21-B08E-42B0-BD5A-C7F06B7008AFQ55008427-049829A3-6EF4-4C30-B057-A1B28A2DBAB2Q55297596-91C5F94D-5271-4D6E-8D52-46B2B78EF53CQ55384068-CADA5C52-C9C3-4726-92D4-0BA143CF9755Q58711392-9F109AEE-F069-4380-B01D-42176F62A67A
P2860
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Camptothecins: from bench research to hospital wards.
@en
type
label
Camptothecins: from bench research to hospital wards.
@en
prefLabel
Camptothecins: from bench research to hospital wards.
@en
P1433
P1476
Camptothecins: from bench research to hospital wards
@en
P2093
Potmesil M
P304
P407
P577
1994-03-01T00:00:00Z